Investment Rationale · True Ventures
Investment thesis
True Ventures seeks to back cross-disciplinary teams combining biology and software to build products impacting patients and consumers.
The founding team of Deep Genomics is a great example of the type of cross-discipline team that we’re interested in backing at the intersection of biology and software, where a deep understanding of both core concepts creates the opportunity for products that will directly affect the life of patients
Why the firm invested
True Ventures invested in Deep Genomics because it combines machine learning and genome biology to transform precision medicine.
I am pleased today to announce our investment in Deep Genomics, a company that is combining world-leading expertise in machine learning and genome biology to transform precision medicine.
Product
Deep Genomics' machine learning technology predicts cellular outcomes when DNA is altered by natural or therapeutic genetic variation.
Deep Genomics’ machine learning technology can tell what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic.
Deep Genomics provides causal interpretations and biological explanations for genetic variations beyond industry standard methods.
This provides causal interpretation for genetic variations, offering a new kind of information beyond industry standard methods.
Deep Genomics' computational engine enables diagnosticians, clinicians, and researchers to connect unknown genetic variants to known variants.
As a result, Deep Genomics’ technology can connect unknown variants to known variants, something that was not previously possible.
Traction
Brendan Frey's research team at the University of Toronto published 47 papers on deep learning in genomics prior to spinning out Deep Genomics.
Collectively, his team has published 47 papers in the space since then. Nine months ago, Brendan and his team spun this research out into Deep Genomics to further push the development of his team’s approach.
What founders can learn
- What actually moved the decision: True Ventures wrote that True Ventures invested in Deep Genomics because it combines machine learning and genome biology to transform precision medicine.
- The traction evidence that carried weight: True Ventures wrote that Brendan Frey's research team at the University of Toronto published 47 papers on deep learning in genomics prior to spinning out Deep Genomics.
Source and provenance
Investment Rationale published by True Ventures on trueventures.com (first-party source). Read the original
